Market news

FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.

XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost.

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.